FID 010
Alternative Names: FID-010Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Fulgent Pharma; University of Southern California
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Nov 2022 Fulgent Pharma has been acquired by Fulgent Genetics
- 27 Oct 2020 Preclinical trials in Cancer in USA (unspecified route), before October 2020 (Fulgent Pharma pipeline, October 2020)